🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Residual Exacerbations With Mepolizumab

Recruitingn/aAges 18 Years - 90 YearsAllLaval University
NCT04578171 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society * Eligible for mepolizumab treatment * Able and willing to sign the informed consent form Exclusion Criteria: * Any respiratory disease apart from asthma * Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome
💊

What it tests

  • Mepolizumab
📍

Where

1 site
Institut universitaire de cardiologie et de pneumologie de Québec
Québec, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy